Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

Aims To report the efficacy and safety of intravitreal bevacizumab (IVB) alone versus IVB plus low-fluence photodynamic therapy (PDT) in age-related macular degeneration (AMD) patients and to verify the occurrence of a synergistic effect of the combined approach on visual acuity, size and morphology of lesion, as well as on the treatment rate. Method Prospective comparative interventional study on 85 patients with treatment-naive classic, or predominantly classic, subfoveal choroidal neovascularisation secondary to AMD. Patients were randomly assigned to group 1 ( IVB injections) and group 2 ( IVB plus low fluence PDT). In group 2, the PDT with verteporfin was delivered with a low fluence rate ( 300 mW/cm(2) for 83 s, 25 J/cm(2)). The follow-up was scheduled at 1, 3, 6, 9 and 12 months. Results The eye without recurrence received a mean of 2.8 ( group 1) versus 1.4 ( group 2) IVB injections, whereas the eyes with recurrence received a mean of 3.2 ( group 1) versus 2.2 ( group 2) IVB injections. The difference in reinjection rate between the two groups was statistically significant (p = 0.03, ANOVA test). Visual acuity improvement was not statistically significant between the two groups (p - 0.31). Conclusion The combination of IVB with low fluence PDT for the treatment of classic or predominantly classic neovascular AMD works in a synergistic fashion with a significant reduction in IVB reinjections rate